Pharma BD Deal Intelligence
Aptevo Therapeutics (Nasdaq: APVO) and Niowave entered a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, with the first program directed at Nectin-4 and pairing Aptevo's proprietary molecule APVO455 with Niowave's Actinium-225 and additional radioisotopes. Executed concurrently were a collaboration agreement (commencing with a proof-of-concept study), a supply agreement under which Niowave supplies radioisotopes to Aptevo, and a stock purchase agreement. At closing Niowave made an at-the-market equity investment giving it an initial ~7.9% ownership position (based on shares outstanding as of May 13, 2026), with the potential to build to up to 19.99% through warrant exercises at a premium and future purchases of Aptevo common stock. No transaction dollar value was disclosed.